Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MAGENTA THERAPEUTICS, INC.

(MGTA)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 03-10-2022
1.380 USD   -2.13%
25/08Magenta Therapeutics, Inc. : Goldman Sachs haalt aandeel van kooplijst
MM
17/08Magenta Therapeutics kondigt de benoeming aan van Michael Vasconcelles tot lid van de Raad van Bestuur, het Comité voor Onderzoek en Ontwikkeling en het Comité voor Benoemingen en Corporate Governance
CI
04/08Magenta Therapeutics, Inc. Rapporteert Winstresultaten voor het Tweede Kwartaal en de Zes Maanden Eindigend op 30 Juni, 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société MAGENTA THERAPEUTICS, INC.
17/08Magenta Therapeutics : Appoints Michael Vasconcelles, M.D. to the Board of Directors - For..
PU
17/08Magenta Therapeutics, Inc. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
17/08Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
AQ
04/08MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
04/08Magenta Therapeutics : Reports Second Quarter Financial Results and Recent Program Highlig..
PU
04/08Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highli..
AQ
02/08Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Hea..
AQ
30/06Magenta Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
16/05MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
16/05Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observatio..
BU
02/05Magenta Therapeutics, Inc. : Change in Directors or Principal Officers, Financial Statemen..
AQ
30/04Magenta Therapeutics : April Corporate Presentation
PU
14/04Magenta Therapeutics : Focuses R&D and Operational Spending, Reduces Workforce and Extends..
PU
14/04Magenta Therapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
14/04Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extend..
BU
08/03MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
08/03Magenta Therapeutics : Reports Fourth Quarter and Full-Year 2021 Financial Results and Rec..
PU
08/03Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Re..
BU
03/03Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Health..
BU
10/01Magenta Therapeutics : J.P. Morgan 2022 Presentation
PU
10/01Magenta Therapeutics : Highlights Recent Pipeline Progress and Milestone Expectations for ..
PU
10/01Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for..
BU
05/01Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Ril..
BU
2021Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization..
BU
2021Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
BU
2021Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Condi..
BU
2021MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
2021Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights - F..
PU
2021Magenta Therapeutics, Inc. : Results of Operations and Financial Condition, Other Events, ..
AQ
2021Magenta Therapeutics : Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
BU
2021Magenta Therapeutics : to Participate in 2021 Cantor Virtual Global Healthcare Conference
BU
2021Magenta Therapeutics : Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical..
BU
2021Magenta Therapeutics : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2021Magenta Therapeutics, Inc. : Results of Operations and Financial Condition, Change in Dire..
AQ
2021Magenta Therapeutics : Reports Second Quarter Financial Results and Recent Program Highlig..
BU
2021Magenta Therapeutics : to Participate in Upcoming Healthcare Investor Conferences in Augus..
BU
2021Magenta Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
2021Magenta Therapeutics : Announces Update on U.S. FDA Investigational New Drug Application f..
BU
2021Magenta Therapeutics : Appoints Caren Deardorf as Chief Commercial Officer
BU
2021Magenta Therapeutics : Appoints Thomas Beetham as Chief Legal Officer
BU
2021Magenta Therapeutics, Inc. : Change in Directors or Principal Officers, Submission of Matt..
AQ
2021Magenta Therapeutics : Announces additional preliminary positive results from ongoing phas..
AQ
2021Magenta Therapeutics : Announces Additional Preliminary Positive Results from Ongoing Phas..
BU
2021Magenta Therapeutics : to Participate in Goldman Sachs 42nd Annual Global Healthcare Confe..
BU
2021Magenta Therapeutics : Departure of Directors or Certain Officers; Election of Directors; ..
PU
2021Magenta Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Inves..
PU
2021Magenta Therapeutics : to Participate in Upcoming Healthcare Investor Conferences in May
BU
2021Magenta Therapeutics : MGTA-145 Ph2 MM Data Review Conference Call Presentation
PU
2021Magenta Therapeutics, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
2021Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Inves..
BU
2021Magenta Therapeutics : Announces Positive Preliminary Results from Phase 2 Clinical Trial ..
BU
2021Magenta Therapeutics : Reports First Quarter Financial Results
PU
2021Magenta Therapeutics : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2021Magenta Therapeutics : Reports First Quarter Financial Results and Recent Program Highligh..
BU
2021Magenta Therapeutics : Appoints David Nichols as Chief Technical Officer
BU
2021Magenta Therapeutics : to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medi..
AQ
2021Magenta Therapeutics : to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medi..
BU
2021Magenta Therapeutics : Presents Final Phase 1 Results
AQ
2021Magenta Therapeutics : Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization C..
BU
2021Magenta Therapeutics : to Present at the Oppenheimer 31st Annual Healthcare Conference
BU
2021Magenta Therapeutics : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
2021Magenta Therapeutics : Reports Fourth Quarter and Full-Year 2020 Financial Results and Rec..
BU
2021Magenta Therapeutics : to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobiliza..
AQ
2021Magenta Therapeutics : to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobiliza..
BU
2021Magenta Therapeutics : Highlights Recent Progress and Expected Timing of 2021 Milestones, ..
BU
2021Magenta Therapeutics : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020Magenta Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2020Magenta Therapeutics : Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 ..
AQ
2020Magenta Therapeutics : Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 ..
BU
2020Magenta Therapeutics : Appoints Steve Mahoney as Chief Financial and Operating Officer
AQ
2020Magenta Therapeutics, Inc. : Change in Directors or Principal Officers, Financial Statemen..
AQ
2020Magenta Therapeutics : Appoints Steve Mahoney as Chief Financial and Operating Officer
BU
2020Magenta Therapeutics : PR, Heidelberg Pharma announces presentations of various research r..
AQ
2020Magenta Therapeutics : Management's Discussion and Analysis of Financial Condition and Res..
AQ
1  2  3Volgende
Volgende evenement op MAGENTA THERAPEUTICS, INC.